Cancer de l'œsophage / jonction œso-gastrique : essais cliniques en Suisse
13 essais ouverts en Suisse pour le cancer de l'œsophage / jonction œso-gastrique et 17 essais ouverts à plusieurs types de cancer, d'après ClinicalTrials.gov, mis à jour le 27 octobre 2026.
Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.
Essais ouverts
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Recrutement en coursPhase 1 · Phase 2
En Suisse : Coire, Genève
- A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Recrutement en coursPhase 1 · Phase 2
En Suisse : Zurich
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Recrutement en coursPhase 1 · Phase 2
En Suisse : Coire, Genève
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Recrutement en coursPhase 1 · Phase 2
En Suisse : Coire, Genève
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
NCT07405151Recrutement en coursPhase 1 · Phase 2
En Suisse : Coire, Genève
- Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
NCT07829081Recrutement en cours
En Suisse : Bâle, Bienne, Lucerne
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Recrutement en coursPhase 1 · Phase 2
En Suisse : Coire, Genève
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Recrutement en coursPhase 1
En Suisse : Coire, Lausanne
- Balloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCE
NCT07355374Recrutement en cours
En Suisse : Bâle
- PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
NCT05055648Recrutement en coursPhase 3
En Suisse : Villigen, Zurich
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NCT04498767Recrutement en cours
En Suisse : Berne, Zurich
- Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma
NCT03222635Recrutement en cours
En Suisse : Zurich
- Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
NCT06361043Recrutement en cours
En Suisse : Berne
Essais ouverts à plusieurs types de cancer
Ces essais acceptent plusieurs types de cancer, peut-être le vôtre : parlez-en à votre médecin.
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
NCT07785609Recrutement en coursPhase 2
En Suisse : Bellinzona, Saint-Gall
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Pas encore en recrutementPhase 2
En Suisse : Lausanne, Saint-Gall
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Recrutement en coursPhase 1
En Suisse : Bellinzona, Saint-Gall
- Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Recrutement en coursPhase 1
En Suisse : Zurich
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Recrutement en coursPhase 2
En Suisse : Berne, Genève, Zurich
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Recrutement en coursPhase 1
En Suisse : Saint-Gall, Winterthour
- Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987Recrutement en coursPhase 1
En Suisse : Bâle, Bellinzona, Berne, Genève
- A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors
NCT07722806Pas encore en recrutementPhase 2
En Suisse : Winterthour
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Recrutement en coursPhase 1
En Suisse : Bellinzona, Lausanne, Saint-Gall
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
NCT07172919Recrutement en coursPhase 2
En Suisse : Bâle
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626Recrutement en coursPhase 1 · Phase 2
En Suisse : Bellinzona, Lucerne
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758Recrutement en coursPhase 1 · Phase 2
En Suisse : Bellinzona
- First in Human Study of T3P-Y058-739 (T3P)
NCT05120596Recrutement en coursPhase 1 · Phase 2
En Suisse : Berne, Lausanne, Zurich
- Tumor Molecular Profiling in Early Phase Clinical Trials
NCT04510766Recrutement en cours
En Suisse : Bellinzona
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485Recrutement en coursPhase 2
En Suisse : Zurich
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
NCT06408688Recrutement en coursPhase 4
En Suisse : Baden, Bâle, Liestal, Saint-Gall
- INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
NCT03838042Recrutement en coursPhase 1 · Phase 2
En Suisse : Zurich